IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Recent Advances in the Delivery of Baclofen in Management of Pain

Nitish Kumar Yadav*[1], Abhay Gupta[1]

Faculty of Pharmacy, Lords University, Alwar, Rajasthan, India

*Corresponding Author

Email id – nitish95348@gmail.com

Abstract

Chronic pain is a significant global health issue, necessitating diverse therapeutic strategies. Baclofen, a muscle relaxant and GABAB receptor agonist, is primarily used for managing spasticity-related pain but faces pharmacokinetic limitations, including a short half-life and poor blood-brain barrier penetration, which complicate its oral administration. This review explores advancements in baclofen delivery systems, focusing on intrathecal baclofen (ITB) therapy, which offers targeted delivery directly to the cerebrospinal fluid, significantly reducing systemic side effects and improving patient compliance. ITB therapy has shown efficacy in severe spasticity and expanding applications in neuropathic pain, Complex Regional Pain Syndrome, and Postherpetic Neuralgia. Emerging delivery methods, including transdermal/topical formulations and nanoparticle-based systems, aim to enhance drug absorption and targeting, potentially offering localized pain relief with fewer systemic effects. Despite promising developments, challenges remain, particularly the need for large-scale clinical trials to validate these novel approaches. Future research should focus on comparative effectiveness studies and personalized treatment strategies to optimize baclofen therapy for chronic pain management.

Keywords

Pain, Baclofen, delivery, bioavailability, sustained release

1. Introduction

Chronic pain represents a pervasive and debilitating global health challenge, necessitating diverse and often multimodal therapeutic strategies. Within this complex landscape, muscle relaxants, particularly baclofen, hold a significant position, especially in addressing pain components associated with spasticity. Baclofen, chemically

a derivative of gamma-aminobutyric acid (GABA), functions as an agonist at the GABAB receptor, primarily at the spinal cord level and in the brain.[1] Its primary FDA-approved indication is the management of reversible spasticity, where it effectively alleviates flexor spasms, clonus, and the pain frequently accompanying these conditions in patients with spinal cord lesions and multiple sclerosis.[1] The pharmacological action of baclofen involves reducing the release of excitatory neurotransmitters from presynaptic neurons and stimulating inhibitory neuronal signals in postsynaptic neurons, thereby mitigating spasticity. It also exhibits an affinity for voltage-gated calcium channels, contributing to its therapeutic effects.[1]

Despite its established efficacy, conventional oral baclofen therapy is constrained by several pharmacokinetic limitations. Baclofen is rapidly absorbed through the gastrointestinal tract, achieving peak plasma concentrations within 2 to 3 hours, and exhibits high bioavailability (70-85%).[1] However, its short elimination half-life, typically ranging from 2 to 6 hours, mandates frequent administration, often multiple times daily, to sustain therapeutic concentrations.[1] This frequent dosing regimen can significantly compromise patient adherence to treatment protocols. A more fundamental challenge lies in baclofen's high water solubility, which impedes its ability to readily traverse the blood-brain barrier (BBB).[1] Consequently, cerebrospinal fluid (CSF) concentrations of the drug following oral administration are considerably lower than plasma concentrations.[1] To achieve adequate central nervous system (CNS) effects, higher systemic doses are often required, which, in turn, escalates the risk of systemic adverse effects.[3]

The inherent pharmacokinetic limitations of oral baclofen, particularly its short half-life and poor blood-brain barrier penetration, represent the fundamental drivers behind the extensive research into advanced drug delivery systems. This pursuit is not merely about identifying alternative administration routes but about overcoming intrinsic biological barriers to maximize therapeutic efficacy within the CNS while simultaneously minimizing undesirable systemic exposure. The need to address these specific issues — achieving effective CNS action without dose-limiting systemic effects and improving patient convenience — underscores the strategic importance of developing targeted or sustained-release methodologies. This review will comprehensively examine recent advancements in baclofen delivery, encompassing established intrathecal approaches, as well as emerging transdermal/topical and nanoparticle-based systems, and their evolving implications for pain management.

2. Oral Baclofen: Pharmacokinetics, Efficacy, and Limitations

Baclofen's pharmacokinetic profile, while demonstrating good absorption, presents significant challenges for sustained therapeutic effect. Following oral administration, baclofen is rapidly absorbed from the gastrointestinal tract, with bioavailability ranging from 70% to 85%. Peak plasma concentrations are typically observed 2 to 3 hours after ingestion, and absorption is noted to be dose-dependent, increasing with higher doses.[1] The drug has a volume of distribution of 0.7 L/kg and is approximately 30% plasma protein bound.[1] Critically, its high water solubility restricts its passage across the blood-brain barrier, leading to significantly lower drug concentrations in

the CSF compared to plasma.[1] Metabolism of baclofen is minimal, with the S-enantiomer forming the S-M1 metabolite in the liver and gut. The majority of the drug (70%) is eliminated unchanged via renal excretion, with the remainder excreted through feces.[1] The short elimination half-life of 2 to 6 hours necessitates frequent dosing throughout the day to maintain optimal therapeutic levels and manage spasticity effectively.[1]

Oral baclofen is predominantly utilized for spasticity, where it is FDA-approved for relieving associated pain, particularly in conditions like spinal cord lesions and multiple sclerosis.[1] Beyond its primary indication, baclofen is also employed off-label for various pain conditions. For instance, it serves as a second-line therapy for trigeminal neuralgia, where it has been observed to reduce the frequency of painful episodes and prolong remission, sometimes in combination with other medications like carbamazepine or phenytoin.[12] It has also been explored as an adjunctive treatment for general muscle spasm and musculoskeletal pain, often in conjunction with nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen.[15]

Despite its therapeutic utility, oral baclofen is associated with a spectrum of common systemic side effects. These include central nervous system (CNS) effects such as drowsiness, fatigue, dizziness, and weakness, as well as gastrointestinal disturbances like nausea, vomiting, and diarrhea.[10] Headaches and sleep problems are also frequently reported.[16] The CNS depressant effects of baclofen can be exacerbated when co-administered with alcohol or other CNS depressants, leading to increased drowsiness.[10] While rare, more severe adverse events include liver problems (indicated by yellowing of eyes or skin), sleep apnea, and an increase in muscle spasms.[16] A critical concern with oral baclofen is the potential for a severe withdrawal syndrome upon abrupt cessation. This can manifest as high fever, altered mental status, exaggerated rebound spasticity, muscle rigidity, and in rare, life-threatening cases, rhabdomyolysis, multiple organ-system failure, and death.[1] Special caution is advised for older adults and patients with impaired renal function, as they face a heightened risk of adverse events such as encephalopathy and falls due to baclofen's primary renal elimination.[1]

The widespread systemic distribution of oral baclofen, a consequence of its limited ability to penetrate the blood-brain barrier, inherently results in a significant clinical trade-off. To achieve effective concentrations at the desired CNS target sites, relatively high systemic doses are often necessary. This elevated systemic exposure, however, frequently leads to dose-limiting systemic adverse effects, such as profound drowsiness or gastrointestinal distress, which can overshadow the therapeutic benefits. This highlights an inherent inefficiency in relying solely on systemic delivery for a centrally acting agent with poor BBB permeability. Furthermore, the combination of a short elimination half-life, which necessitates frequent daily dosing, and the high incidence of bothersome systemic side effects profoundly impacts patient adherence to prescribed regimens and overall quality of life. Patients may struggle to maintain consistent dosing due to inconvenience or discontinue the medication altogether to avoid side effects, leading to suboptimal symptom control. This underscores the pressing clinical need for alternative delivery methods that can circumvent these limitations and offer a more favorable therapeutic profile.

3. Intrathecal Baclofen (ITB) Therapy: A Targeted Approach

Intrathecal baclofen (ITB) therapy represents a significant advancement in the management of severe spasticity and associated pain, offering a highly targeted approach that overcomes many limitations of oral administration. This therapy involves the surgical implantation of a programmable pump and a catheter system designed to deliver baclofen directly into the cerebrospinal fluid (CSF) within the spinal canal.[1] This direct delivery bypasses the blood-brain barrier, allowing baclofen to reach its target GABAB receptors on spinal cord neurons at significantly lower doses—often less than 1% of the oral dose—to achieve therapeutic concentrations.[3]

Over the years, ITB pump technology has undergone continuous evolution, focusing on enhancing precision, safety, and user-friendliness. Modern implantable pumps feature improved programmability, enabling healthcare providers to tailor dosing schedules precisely to individual patient needs, including continuous infusions or programmed boluses at different times of the day.[1] Miniaturization of devices has made implantation less invasive, and advancements in battery technology have extended pump lifespan to 5-7 years, reducing the frequency of surgical replacements.[20] Wireless communication capabilities further enhance monitoring and adjustment of pump settings, contributing to more personalized and effective pain management.[27]

The advantages of ITB therapy are substantial:

- **Targeted Delivery and Reduced Systemic Side Effects:** By delivering baclofen directly to the spinal cord, ITB minimizes systemic exposure. This significantly reduces the incidence and severity of systemic side effects commonly associated with oral baclofen, such as generalized drowsiness, confusion, and gastrointestinal disturbances.[3]
- **Continuous and Programmable Infusion:** ITB pumps provide a continuous, precise infusion of baclofen, maintaining stable therapeutic levels in the CSF. This contrasts sharply with the fluctuating plasma concentrations inherent to oral dosing due to baclofen's short half-life. The programmability allows for highly individualized dosing, adapting to a patient's changing needs throughout the day or night.[1]
- **Improved Efficacy for Severe Conditions:** ITB is particularly indicated for severe, intractable spasticity of cerebral or spinal cord origin that has proven unresponsive to or intolerable of maximum oral doses of baclofen or other antispasticity medications.[3] It has been shown to significantly decrease spasticity and spasms, leading to improvements in muscle movement, overactive reflexes, and increased range of motion.[18]

Patients considered candidates for ITB therapy typically present with severe spasticity that significantly interferes with their function, daily activities, care, or comfort, and have not achieved adequate relief or have experienced intolerable CNS side effects with oral baclofen.[18] For spasticity resulting from traumatic brain injury, it is generally recommended to wait at least one year post-injury before considering long-term ITB therapy.[18] A crucial prerequisite for implantation is that the patient must be free of infection.[18]

ITB therapy has demonstrated efficacy across a range of pain conditions:

- **Spasticity-Related Pain:** As its primary indication, ITB effectively manages pain directly resulting from muscle spasms and stiffness.[1] Long-term studies, including a cohort treated for over a decade, report sustained efficacy with low levels of pain and infrequent spasms, alongside high patient satisfaction.[33]
- **Neuropathic Pain:** Beyond spasticity, ITB has shown promising long-term analgesic effects on neuropathic pain, particularly in patients with spinal cord injury (SCI).[34] Case series have documented significant improvements in neuropathic pain scores (e.g., 60-80% reduction) and a substantial decrease in the impact of pain on daily living activities.[34] ITB has been observed to reduce paroxysmal pain and dysesthesia, and improve pain interference with general activity in SCI individuals.[36]
- **Complex Regional Pain Syndrome (CRPS) and Postherpetic Neuralgia (PHN):** ITB pumps have been successfully utilized to control severe pain associated with CRPS, sometimes in conjunction with spinal cord stimulators.[28] Evidence suggests ITB can effectively reduce CRPS pain, potentially offering an advantage over intrathecal morphine in some cases due to a more favorable side effect profile.[28] For intractable PHN, intrathecal baclofen is considered a safe and effective therapeutic modality, with reports of marked improvement in stabbing, throbbing, and burning sensations.[38]
- **Trigeminal Neuralgia (TN):** While oral baclofen is a recognized second-line therapy for TN, reducing painful episodes and extending remission [12], specific ITB studies for TN are less prevalent in the provided literature. However, baclofen's central mechanism of action suggests potential for severe, refractory cases.
- **Chronic Non-Cancer Pain (CNCP):** Intrathecal infusion systems, which can deliver baclofen, are employed for intractable CNCP when other treatments have failed.[20] Although large-scale randomized controlled trials are limited, supportive prospective open studies indicate long-term pain relief and improved quality of life.[24] The ability to administer lower doses and reduce systemic side effects is a significant advantage over systemic opioid administration for CNCP.[9]

Long-term outcomes for ITB therapy are generally favorable. Patients treated with ITB for over a decade have reported sustained efficacy, low pain levels, moderate life satisfaction, and high overall satisfaction with the therapy.[33] Beyond pain reduction, ITB therapy can improve functional aspects such as gait, hygiene, and ease of care, and promote tone reduction, all contributing positively to a patient's overall quality of life.[18]

Despite its profound benefits, ITB therapy carries potential complications:

- **Surgical Risks:** As with any surgical procedure, there are inherent risks including infection at the surgical site, bleeding, bruising, and leakage of spinal fluid.[9]
- **Baclofen Withdrawal Syndrome:** An abrupt interruption of ITB delivery, whether due to pump malfunction, catheter issues, or missed refill appointments, constitutes a life-threatening medical emergency. Symptoms can rapidly escalate to high fever, altered mental status, exaggerated rebound spasticity, muscle rigidity, and in rare, severe cases, rhabdomyolysis, multiple organ-system failure, and death.[1]

- **Overdose:** Although rare, baclofen overdose can occur, typically near pump refill or programming changes. Symptoms include profound drowsiness, severe muscle weakness, low blood pressure and temperature, difficulty breathing, loss of consciousness, and seizures, and can also be life-threatening.[8]
- **Tolerance:** In some cases of prolonged treatment (documented in 5.9% of cases), patients may develop tolerance, requiring escalating doses to maintain clinical efficacy.[23] A "baclofen holiday," involving temporary cessation of baclofen (often with concurrent opioid infusion), may be considered to restore sensitivity.[23]
- **Device-Related Issues:** Catheter-related failures, such as migration, kinking, blockage, or disconnection, are reported as the most common complications, alongside pump malfunction or erosion through the skin.[20]

ITB therapy represents a significant shift in the approach to pain management for refractory conditions. By enabling highly targeted drug delivery directly to the spinal cord, it offers a superior therapeutic profile for severe, otherwise intractable pain and spasticity, with a dramatically improved systemic side-effect burden compared to oral administration. This is not merely an alternative treatment; for specific patient populations, it often proves to be a more effective and appropriate primary strategy. However, this enhanced efficacy comes with a critical caveat: the direct CNS delivery of baclofen introduces unique and potentially life-threatening risks, such as withdrawal syndrome and overdose. These necessitate highly specialized medical management, meticulous patient monitoring, and comprehensive patient education regarding pump maintenance and refill schedules. The expanding evidence for ITB's efficacy in various pain conditions beyond its traditional role in spasticity, including neuropathic pain, Complex Regional Pain Syndrome, and Postherpetic Neuralgia, further suggests an evolving understanding of baclofen's broader analgesic properties. This broadening scope opens new avenues for its clinical application in complex pain syndromes where conventional treatments may fall short.

To illustrate the distinct characteristics and advantages of ITB therapy compared to conventional oral baclofen, a comparative overview is presented in Table 1.

Table 1: Comparison of Oral vs. Intrathecal Baclofen Delivery for Pain Management

Feature	**Oral Baclofen**	**Intrathecal Baclofen (ITB) Therapy**
Route of Administration	Systemic (oral tablets/liquid)	Localized (implanted pump/catheter into CSF)
Target Site	Systemic circulation, indirect CNS access	Direct to spinal cord/CSF

Dose Required (relative)	High systemic doses	Low micro-doses (<1% of oral dose)
Blood-Brain Barrier Penetration	Poor	Bypassed
Pharmacokinetics	Short half-life (2-6h), fluctuating plasma levels, frequent dosing	Continuous, stable CSF levels, less frequent refills (1-6 months)
Primary Indications	Reversible spasticity, associated pain, off-label TN, musculoskeletal pain	Severe, refractory spasticity (cerebral/spinal origin), expanding to neuropathic pain, CRPS, PHN, CNCP
Common Side Effects	Systemic: Drowsiness, dizziness, nausea, fatigue, GI issues	Localized/Fewer systemic: Hypotonia, headaches; critical risks of withdrawal/overdose
Patient Compliance	Challenging due to frequent dosing and systemic side effects	Improved due to stable control and less frequent refills
Reversibility	Easy discontinuation (with tapering to avoid withdrawal)	Surgical removal of device

4. Emerging Advanced Delivery Systems for Baclofen

Beyond the established intrathecal delivery, significant research and development are ongoing to explore novel baclofen delivery systems that aim to further optimize its therapeutic profile for pain management. These emerging approaches, including transdermal/topical formulations and nanoparticle-based systems, represent a crucial diversification in baclofen delivery, moving beyond systemic and intrathecal routes to offer more tailored, localized, or brain-targeted options for specific pain phenotypes. This allows for a more precise and individualized approach to baclofen administration.

4.1. Transdermal and Topical Formulations

Transdermal and topical delivery systems offer attractive alternatives to oral administration by delivering drugs through the skin. Transdermal patches aim for systemic absorption, while topical formulations target localized areas. Both approaches seek to circumvent the limitations of oral delivery, such as first-pass hepatic metabolism and systemic side effects, while potentially enhancing patient convenience and compliance.[5] The skin's extensive surface area and rich vascularization make it an appealing route for drug delivery.[5]

Recent research has focused on developing baclofen microemulsions and integrating them into transdermal patches to improve drug permeability and solubility across the skin barrier.[5] Studies have demonstrated high in-vitro permeation release rates, with microemulsions achieving 88.79% release in 8 hours and baclofen microemulsion patches showing 97.67% release.[5] These patch formulations are designed to provide a sustained drug release over several hours, for example, a 4-hour duration.[5]

Clinical evidence for topical baclofen in pain management is emerging:

- **Diabetic Peripheral Neuropathy (DPN):** A placebo-controlled, double-blind clinical trial (March 2022) investigated the analgesic effects of baclofen 5% topical cream for DPN. While initial analysis indicated better outcomes for the baclofen group, adjusted analysis showed no significant differences in DN4 scores between the groups, although scores significantly reduced in both. Notably, no side effects were reported by any participant in the study, suggesting a favorable safety profile for topical baclofen as a potential intervention for localized neuropathic pain.[44]
- **Post-Hemorrhoidectomy Pain:** Topical application of baclofen has also demonstrated effectiveness in alleviating post-hemorrhoidectomy pain. A study reported significantly lower pain scores and reduced analgesic consumption in the baclofen group compared to placebo at weeks 1 and 2 post-surgery, with minimal observed side effects.[46]
- **Compounded Transdermal Gels:** Compounding pharmacies offer baclofen 2% transdermal gel as a specialized formulation for the localized treatment of muscle symptoms, including spasticity, spasms, and pain, in conditions such as multiple sclerosis and spinal cord injury.[43] This formulation is applied directly to the affected area, aiming to provide targeted relief while minimizing systemic exposure and associated side effects.[43]

4.2. Nanoparticle-Based Delivery Systems

Nanotechnology offers a transformative approach to pain management by creating drug delivery systems that can improve drug stability, enhance solubility, control release efficiency, modify pharmacokinetic characteristics, and facilitate targeted delivery with potentially fewer side effects.[47] This approach can lead to prolonged analgesic effects and a reduction in administration frequency.[47]

Research has specifically focused on developing baclofen-loaded Poly Lactic-co-Glycolic Acid (PLGA) nanoparticles (Bcf-PLGA-NPs) for neuropathic pain management.[49] In-vitro evaluations of these nanoparticles, with an average size of 124.8 nm, demonstrate sustained release profiles; for instance, 80-85% of baclofen was released over 24 hours in phosphate-buffered saline, with slower release rates observed in simulated nasal fluid and cerebrospinal fluid.[49] Furthermore, these nanoparticles exhibit low cytotoxicity, indicating their potential as safe carrier systems.[49]

A particularly promising area is the in-vivo evaluation of Bcf-PLGA-NPs via the nose-to-brain pathway. Preclinical studies in rats, utilizing radiolabeled nanoparticles, showed maximum uptake in the brain via intranasal administration at 3 hours, with the drug persisting for 24 hours.[49] This finding is significant because the intranasal route offers a non-invasive means to bypass the blood-brain barrier, leading to higher drug availability in the brain and potentially reducing peripheral side effects.[49] The calculated Drug Targeting Efficiency (DTE%) of 183.85% for intranasal delivery compared to intravenous administration further supports the efficient accumulation of baclofen in the brain region.[49] This demonstrates that nanoparticle-based delivery, particularly via the intranasal route, holds transformative potential for baclofen. It effectively bypasses the blood-brain barrier and enables sustained drug release directly to the CNS, thereby overcoming key limitations of both oral and even intrathecal administration for certain central pain conditions. This non-invasive approach to achieving high CNS concentrations and sustained action could significantly improve patient compliance by reducing dosing frequency.

While specific studies on baclofen encapsulated in liposomes are not extensively detailed in the provided information, the general principles of liposomal drug delivery are highlighted as having significant potential for pain treatment.[47] Liposomes, composed of non-toxic cholesterol and phospholipids, are capable of encapsulating both hydrophilic and hydrophobic drugs. They offer advantages such as good biocompatibility, biodegradability, low toxicity, high loading capacity, and prolonged retention and permeability.[47] Examples with other local anesthetics, such as bupivacaine, prilocaine, lidocaine, and mepivacaine, have demonstrated improved half-life, bioavailability, and prolonged postoperative pain control when delivered via liposomes.[47] This provides a strong theoretical foundation for similar benefits if baclofen were to be successfully formulated into liposomal carriers.

4.3. Sustained-Release Oral Formulations

Addressing baclofen's short half-life and the need for frequent dosing with oral administration has been a persistent challenge. While efforts to develop sustained-release oral baclofen formulations have been attempted, previous endeavors faced significant hurdles, including issues like "dose dumping," where the entire drug dose is released too rapidly, leading to potential toxicity or loss of sustained effect.[5]

Despite these challenges, recent studies continue to explore innovative oral sustained-release technologies. For instance, research published in 2024 has investigated floating bilayer films designed for sustained oral release of

baclofen. These films aim to prolong gastric residence time, thereby improving absorption and maintaining therapeutic levels over an extended period.[52] An optimized formulation in one study achieved 98% drug release within 12 hours and maintained buoyancy for 24 hours, following zero-order kinetics, indicating a controlled and steady release profile.[52] Additionally, orodispersible tablets are being developed as another strategy to enhance patient compliance, particularly for individuals with swallowing difficulties, by facilitating rapid drug release and ease of administration.[7] The persistent challenge of developing a truly effective and safe sustained-release oral baclofen formulation underscores the complexity of overcoming its inherent pharmacokinetic properties, such as a narrow absorption window and the aforementioned dose dumping issues. This suggests that while oral modifications are pursued, other, more radical delivery innovations like intrathecal or nanoparticle systems have shown more definitive success in circumventing baclofen's pharmacokinetic constraints.

The emergence of transdermal/topical and nanoparticle-based systems signifies a crucial diversification in baclofen delivery. This evolution moves beyond the traditional systemic and invasive intrathecal routes to offer more tailored, localized, or brain-targeted approaches for specific pain phenotypes. This allows for a level of precision in baclofen delivery that was previously unattainable, enabling clinicians to select the most appropriate delivery method based on the pain's etiology and anatomical location.

Table 2: Summary of Recent Advances in Novel Baclofen Delivery Systems for Pain Management

Delivery System Type	Key Features/Mechanism	Advantages for Pain Management	Current Status/Evidence	Challenges/Limitations
Transdermal Patch/Gel	Localized skin absorption, microemulsion enhancement	Reduced systemic side effects, targeted action, improved compliance	Clinical trials (DPN, post-hemorrhoidectomy), compounded formulations	Skin irritation, need for more human trials
Nanoparticles (PLGA)	Encapsulation, sustained release,	Targeted brain delivery,	Preclinical (in-vitro/in-vivo rat studies)	Need for large-scale human clinical trials

	intranasal BBB bypass	prolonged effect, reduced systemic side effects		
Liposomes	Encapsulation of drugs, good biocompatibility	Improved drug stability, controlled release, targeted delivery, prolonged effect	General potential, examples with other local anesthetics	Specific baclofen liposomal studies are limited
Sustained-Release Oral	Prolonged gastric residence (floating films), rapid dissolution (orodispersible)	Reduced dosing frequency, improved compliance	Floating bilayer films (preclinical), orodispersible tablets (development)	Previous "dose dumping" issues, complexity of sustained oral release

5. Future Directions and Conclusion

Recent years have witnessed remarkable progress in baclofen delivery for pain management, transitioning from conventional oral administration to highly targeted and innovative approaches. Intrathecal baclofen therapy has solidified its position as a cornerstone for severe spasticity-related pain and has demonstrated increasing utility in complex neuropathic pain syndromes, Complex Regional Pain Syndrome (CRPS), and Postherpetic Neuralgia (PHN). Simultaneously, emerging technologies such as transdermal/topical formulations and nanoparticle-based systems are expanding the frontiers of localized and brain-targeted delivery, promising enhanced efficacy with a reduced systemic burden.

Despite these exciting advancements, several unmet needs and critical areas for future research remain. The most significant challenge for the widespread clinical adoption of novel delivery systems, particularly nanoparticle-based approaches, lies in the scarcity of robust, large-scale human clinical trials. While preclinical data for

systems like intranasal PLGA-nanoparticles are highly promising, the critical bottleneck for their integration into real-world patient care is the need for comprehensive validation of their efficacy and safety in diverse human pain populations. For ITB in chronic non-cancer pain, it is noted that randomized controlled trials are still limited, highlighting a persistent gap between observed benefits and the highest level of evidence. More long-term efficacy data are also required for all emerging delivery methods, especially for non-spasticity pain conditions, to firmly establish sustained benefits and identify any potential long-term complications or patterns of tolerance.

Future research should prioritize comparative effectiveness studies that directly compare different advanced delivery systems for specific pain conditions. Such research would provide invaluable evidence to inform clinical decision-making and optimize treatment algorithms. Furthermore, delving deeper into patient-specific factors, such as genetics and pain phenotype, that influence individual responses to various delivery methods could pave the way for truly personalized baclofen therapy. Strategies to mitigate or reverse the development of tolerance to ITB, including optimizing dosing regimens or exploring co-administration with synergistic agents, also remain crucial areas of investigation.

These advancements in baclofen delivery hold immense potential to profoundly impact clinical practice and patient outcomes in pain management. By enabling targeted, sustained, and more patient-friendly drug delivery, they can offer improved pain relief, a reduction in debilitating side effects, enhanced quality of life, and better functional outcomes for individuals suffering from a wide spectrum of chronic pain conditions, particularly those refractory to conventional treatments. Beyond individual patient benefits, the development of delivery methods that reduce systemic drug exposure contributes significantly to broader public health objectives. By providing effective pain management alternatives, these innovations can help mitigate risks associated with conventional systemic analgesics, including the growing concerns around opioid dependence and overdose, thereby fostering a safer and more diversified landscape for pain care.

Works cited

1. Baclofen - StatPearls - NCBI Bookshelf, accessed on May 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK526037/

2. Baclofen - Wikipedia, accessed on May 23, 2025, https://en.wikipedia.org/wiki/Baclofen

3. Romito JW, Turner ER, Rosener JA, et al. Baclofen therapeutics, toxicity, and withdrawal: A narrative review. SAGE Open Med. 2021; 9: 20503121211022197

4. Baclofen: Uses, Interactions, Mechanism of Action. DrugBank Online, accessed on May 23, 2025, https://go.drugbank.com/drugs/DB00181

5. Panghal A, Sachedeva M, Agarwal V. Formulation & Development of Baclofen microemulsion incorporated into Transdermal patch. Journal of Drug Delivery and Therapeutics. 2022; 12(5): 55-63

6. Baclofen for Spasticity Reviews - Drugs.com, accessed on May 23, 2025, https://www.drugs.com/comments/baclofen/for-spasticity.html

7. Manjanna KM, Mounika C, Govind Reddy G, et al. Development and Evaluation of Baclofen Orodispersible Tablets by Sublimation Method. Journal of Drug Delivery and Therapeutics. 2025; 15(5): 23-24

8. Targeted Delivery for Effective Control - HCP - Lioresal Intrathecal (baclofen injection), accessed on May 23, 2025, https://lioresal.com/hcp/dosing-and-administration/targeted-delivery-for-effective-control/

9. Intrathecal Pain Pump. Johns Hopkins Medicine, accessed on May 23, 2025, https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/intrathecal-pain-pump

10. Baclofen - NHS, accessed on May 23, 2025, https://www.nhs.uk/medicines/baclofen/about-baclofen/

11. Baclofen (oral route) - Mayo Clinic, accessed on May 23, 2025, https://www.mayoclinic.org/drugs-supplements/baclofen-oral-route/description/drg-20067995

12. Pino MA. Trigeminal Neuralgia: A "Lightning Bolt" of Pain - U.S. Pharmacist, 2017. accessed on May 23, 2025, https://www.uspharmacist.com/article/trigeminal-neuralgia-a-lightning-bolt-of-pain

13. Baclofen (Lioresal) - MS Trust, accessed on May 23, 2025, https://mstrust.org.uk/a-z/baclofen-lioresal-lyflex

14. Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Annals in Neurology. 1984; 15(3): 240-244

15. Baclofe. Pediatric Care Online, accessed on May 23, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5606/Baclofen

16. Side effects of baclofen - NHS, accessed on May 23, 2025, https://www.nhs.uk/medicines/baclofen/side-effects-of-baclofen/

17. Baclofen Tablets: Uses, Interactions & Side Effects - Cleveland Clinic, accessed on May 23, 2025, https://my.clevelandclinic.org/health/drugs/19760-baclofen-tablets

18. Intrathecal Baclofen Therapy - Patient Selection. Medtronic, accessed on May 23, 2025, https://www.medtronic.com/ph-en/healthcare-professionals/therapies-procedures/neurological/intrathecal-baclofen-therapy/education-training/patient-selection.html

19. Zhu LL, Wang YH, Zhou Q. Tizanidine: Advances in Pharmacology & Therapeutics and Drug Formulations. Journal of Pain Research. 2024; 17: 1257-1271

20. CG-SURG-79 Implantable Infusion Pumps, accessed on May 23, 2025, https://www.anthem.com/medpolicies/abc/active/gl_pw_d080206.html

21. Baclofen Pump: What It Is, Side Effects & Complications - Cleveland Clinic, accessed on May 23, 2025, https://my.clevelandclinic.org/health/treatments/8997-intrathecal-baclofen-pump

22. Baclofen (intrathecal route) - Mayo Clinic, accessed on May 23, 2025, https://www.mayoclinic.org/drugs-supplements/baclofen-intrathecal-route/description/drg-20062155

23. Claudia de la Fuente, Benito J, Vidal J, et al. Tolerance to intrathecal baclofen: clinical case report - Revista de la Sociedad Española del Dolor. 2024; 31(1): 40-44

24. Intrathecal drug delivery for the management of pain and spasticity in adults; recommendations for best clinical practice, 2008. accessed on May 23, 2025, https://www.britishpainsociety.org/static/uploads/resources/files/book_ittd_main.pdf

25. Intrathecal drug delivery for the management of pain and spasticity in adults; recommendations for best clinical practice, 2015. accessed on May 23, 2025, https://www.britishpainsociety.org/static/uploads/resources/files/itdd_2015_pro_v3.pdf

26. Intrathecal Pain Pump - A Review | Twin Cities Pain Clinic, accessed on May 23, 2025, https://twincitiespainclinic.com/intrathecal-pump-a-review/

27. Intrathecal Pumps Market Share, Growth Analysis. CAGR of 5.4%, accessed on May 23, 2025, https://media.market.us/intrathecal-pumps-market-news/

28. Intrathecal Pump Therapy as a Treatment for Complex Regional Pain Syndrome, accessed on May 23, 2025, https://illinoispain.com/blog/intrathecal-pump-therapy-treatment-complex-regional-pain-syndrome/

29. Intrathecal Baclofen (ITB) Therapy Systems Market Trends: Drivers, Restraints and Growth Factors (2024-2033) - Emergen Research, accessed on May 23, 2025, https://www.emergenresearch.com/industry-report/intrathecal-baclofen-therapy-systems-market/market-trends

30. Intrathecal Pumps - MarketResearch.com, accessed on May 23, 2025, https://www.marketresearch.com/Global-Industry-Analysts-v1039/Intrathecal-Pumps-40765370/

31. Atlanta Baclofen Pump Surgery. Kennesaw ITB Therapy, accessed on May 23, 2025, https://medicimedicalarts.com/baclofen-pump/

32. Surgery to Implant the Baclofen Pump for Severe Spasticity due to Cerebral Palsy, accessed on May 23, 2025, https://www.medtronic.com/en-ca/l/your-health/treatments-therapies/cerebral-palsy/getting-therapy.html

33. Mathur SN, Chu SK, McCormick Z. Long-term intrathecal baclofen: outcomes after more than 10 years of treatment. 2014; 6(6): 506-513

34. Kumru H, Albu S, Kofler M, et al. The long-term analgesic effect of intrathecal baclofen on neuropathic pain in patients with spinal cord injury. Neurología (English Edition). 2019; DOI: 10.1016/j.nrleng.2019.09.006

35. Kumru H, Albu S, Kofler M, et al. Long-term use of intrathecal baclofen reduces neuropathic pain and its interference with general activity in spinal cord injury individuals. Acta Neurologica Belgica. 2024; 124(5): 1631-1640

36. Ko MJ, Lee HS, Jo H, et al. Intrathecal baclofen pump implantation for complex regional pain syndrome in a patient with a spinal cord stimulator. Anesthesia and Pain Medicine. 2018; 13(2): 201-206

37. Intrathecal Infusion Pump for Pain Medications or Baclofen. Total Body Pain Institute, accessed on May 23, 2025, https://totalbodypaininstitute.com/intrathecal-infusion-pump-for-pain-medications-or-baclofen

38. Hosny A, Simopoulos T, Collins B. Response of Intractable Post Herpetic Neuralgia to Intrathecal Baclofen. Pain Physician. 2004; 7: 345-347

39. Falco FJE, Patel V, Hayek SM, et al. Intrathecal Infusion Systems for Long-Term Management of Chronic Non-Cancer Pain: An Update of Assessment of Evidence. Pain Physician. 2013; 16: SE185-SE216

40. Comber ER, Strong J, Moore O, et al. Evaluation of long-term outcomes with intrathecal opioid treatment: a comparison utilizing data derived from pain clinic populations in Australia and New Zealand. Frontiers in Pain and Research. 2025; 6. https://doi.org/10.3389/fpain.2025.1527371

41. Duarte RV, Lambe T, Raphael JH, et al. Intrathecal drug delivery systems for the management of chronic non-cancer pain: protocol for a systematic review of economic evaluations. BMJ Open. 2016; 6(7): e012285.

42. Baclofen 2% Transdermal Gel - Compounded Pain Support ..., accessed on May 23, 2025, https://www.bayviewrx.com/formulas/Baclofen-2-Transdermal-Gel-Spasticity-Multiple-Sclerosis-Cerebral-Palsy-Spinal-Cord-Injury-Stroke

43. Ala S, Enayatifard R, Monajati M, et al. The Analgesic Effects of Baclofen 5% Topical Cream for Treatment of Diabetic Peripheral Neuropathy: a Placebo-Control and Double-Blinded Clinical Trial. SN Comprehensive Clinical Medicine. 2022; 4(1). Doi: 10.1007/s42399-021-01108-7

44. How Do Skeletal Muscle Relaxants Fit Into Pain Management?, accessed on May 23, 2025, https://www.managedhealthcareexecutive.com/view/where-do-skeletal-muscle-relaxants-fit-into-pain-management-

45. Xu Y, Dong X, Xu H, et al. Nanomaterial-Based Drug Delivery Systems for Pain Treatment and Relief: From the Delivery of a Single Drug to Co-Delivery of Multiple Therapeutics. Pharmaceutics. 2023; 15(9): 2309.

46. Torpey A, Bellow E, Samojedny V, et al. Nanotechnology in Pain Management. Pharmaceutics. 2014; 16(11): 1479.

47. Nigam K, Kaur A, Manda K, et al. Baclofen-loaded PLGA nanoparticles for neuropathic pain management: In-vitro and In-vivo evaluation. Rejuvenation Research. 2018; 22(3). Doi: 10.1089/rej.2018.2119

48. Anesthesiology and Perioperative Medicine - Clinical trials - Mayo Clinic, accessed on May 23, 2025, https://www.mayoclinic.org/departments-centers/anesthesiology-and-perioperative-medicine/sections/clinical-trials/rsc-20507846

49. Pain Medicine - Clinical trials - Mayo Clinic, accessed on May 23, 2025, https://www.mayoclinic.org/departments-centers/pain-medicine/sections/clinical-trials/rsc-20450103

50. Muter SS, Habeeb AD. Preparation and evaluation of gastroretentive floating unfolding film of baclofen – Pharmacia. 2025; 72: 1-12